Genomic Health Receives a Hold from Jefferies

By Jason Carr

In a report issued on September 12, Eun Yang from Jefferies reiterated a Hold rating on Genomic Health (NASDAQ: GHDX), with a price target of $33. The company’s shares opened today at $31.22.

According to, Yang is a 4-star analyst with an average return of 5.8% and a 52.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, DBV Technologies SA – American, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Genomic Health is Moderate Buy and the average price target is $33.25, representing a 6.5% upside.

In a report issued on August 28, Cowen & Co. also reiterated a Hold rating on the stock with a $34 price target.

Based on Genomic Health’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $85.49 million and GAAP net loss of $2.74 million. In comparison, last year the company earned revenue of $81.97 million and had a GAAP net loss of $6.1 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Genomic Health, Inc. engages in the development and global commercialization of genomic- based clinical laboratory services that analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. Its uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott and Steven Shak in August 2000 and is headquartered in Redwood City, CA.